SERUM PROTEOMIC PREDICTION OF OUTCOMES IN ADVANCED NSCLC PATIENTS TREATED WITH ERLOTINIB/PLACEBO IN THE NCIC CLINICAL TRIALS GROUP BR.21 TRIAL

被引：0
|
作者：
Carbone, D. P. [1 ]
Seymour, L. [2 ]
Ding, K. [3 ]
Roder, H. [4 ]
Tsao, M. [5 ]
Shepherd, F. A. [5 ]
机构：
[1] Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN USA
[2] Queens Univ, Ncic Ctg, Toronto, ON, Canada
[3] Queens Univ, Commun Hlth & Epidemiol, Kingston, ON K7L 3N6, Canada
[4] Biodesix Inc, Broomfield, CO USA
[5] Princess Margaret Hosp, Toronto, ON, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [31] ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR. 24 trial of platinum-treated advanced stage non-small cell lung cancer patients
    Cuffe, Sinead
    Azad, Abul Kalam
    Qiu, Xiaoping
    Qiu, Xin
    Brhane, Yonathan
    Kuang, Qin
    Marsh, Sharon
    Savas, Sevtap
    Chen, Zhuo
    Cheng, Dangxiao
    Leighl, Natasha B.
    Goss, Glenwood
    Laurie, Scott A.
    Seymour, Lesley
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Tsao, Ming Sound
    Chen, Bingshu E.
    Xu, Wei
    Liu, Geoffrey
    CANCER EPIDEMIOLOGY, 2016, 41 : 50 - 56
  • [32] Outcomes of patients with peripheral T-cell lymphoma: a subset analysis of the NCIC Clinical Trials Group LY.12 Phase III clinical trial
    Hay, A. E.
    Savage, K. J.
    Crump, M.
    Reiman, A.
    Meyer, R. M.
    Good, D.
    LeBrun, D. P.
    Kuruvilla, J.
    Djurfeldt, M. S.
    Chen, B. E.
    Shepherd, L. E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 53 - 54
  • [33] Identifying patients with non-small cell lung cancer (NSCLC) unlikely to benefit from erlotinib: An exploratory analysis of National Cancer of Institute of Canada Clinical Trials Group BR.21.
    Florescu, M.
    Hasan, B.
    Shepherd, F. A.
    Seymour, L.
    Ding, K.
    Pater, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 404S - 404S
  • [34] Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21
    Clark, Gary M.
    Zborowski, Denni M.
    Santabarbara, Pedro
    Ding, Keyue
    Whitehead, Marlo
    Seymour, Lesley
    Shepherd, Frances A.
    CLINICAL LUNG CANCER, 2006, 7 (06) : 389 - 394
  • [35] DIFFERENT OUTCOMES IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) TREATED WITHIN OR OUTSIDE CONTROLLED CLINICAL TRIALS
    Rovere, Giulia
    Vavala, Tiziana
    Longo, Marina
    Pessina, Paolo
    Capelletto, Enrica
    Demichelis, Sara
    Rapetti, Simonetta G.
    Crida, Benedetta
    Novello, Silvia
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1187 - S1188
  • [36] Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
    Buttigliero, Consuelo
    Shepherd, Frances A.
    Barlesi, Fabrice
    Schwartz, Brian
    Orlov, Sergey
    Favaretto, Adolfo G.
    Santoro, Armando
    Hirsh, Vera
    Ramlau, Rodryg
    Blackler, Adele R.
    Roder, Joanna
    Spigel, David
    Novello, Silvia
    Akerley, Wallace
    Scagliotti, Giorgio V.
    ONCOLOGIST, 2019, 24 (06): : E251 - E259
  • [37] BIOMARKER ANALYSIS OF NCIC CLINICAL TRIALS GROUP IND.196, A PHASE I STUDY OF ERLOTINIB PLUS FORETINIB IN ADVANCED PRETREATED NON-SMALL CELL LUNG CANCER PATIENTS
    Leighl, Natasha
    Tsao, Ming S.
    Sakashita, Shingo
    Tu, Dongsheng
    Ho, Cheryl
    Shepherd, Frances A.
    Murray, Nevin
    Nicholas, Garth
    Goffin, John R.
    Kim, Lucia
    Kamel-Reid, Suzanne
    Ho, James
    Zhang, Tong
    Sukhai, Mahadeo
    Seymour, Lesley
    Goss, Glenwood
    Bradbury, Penelope
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S330 - S331
  • [38] A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29
    Laurie, Scott Andrew
    Solomon, Benjamin J.
    Seymour, Lesley
    Ellis, Peter Michael
    Goss, Glenwood D.
    Shepherd, Frances A.
    Boyer, Michael J.
    Arnold, Andrew Michael
    Clingan, Philip
    Laberge, Francis
    Fenton, Dave
    Hirsh, Vera
    Zukin, Mauro
    Stockler, Martin R.
    Lee, Christopher W.
    Chen, Eric Xueyu
    Montenegro, Alexander
    Ding, Keyue
    Bradbury, Penelope Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] SERUM PROTEOMIC CLASSIFIER FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH ERLOTINIB AND BEVACIZUMAB IN FIRST LINE: POOLED ANALYSIS OF PHASE II TRIALS SAKK19/05 AND NTR528
    Gautschi, O.
    Dingemans, A. C.
    Crowe, S.
    Roder, H.
    Zappa, F.
    Pless, M.
    Brutsche, M.
    Peters, S.
    Carbone, D.
    Smit, E. F.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S30 - S31
  • [40] Known brain metastases: a valid exclusion criterion in non-small cell lung cancer (NSCLC) clinical trials? An audit of the eligibility criteria in NSCLC trials, and an evaluation of treatment delivery, toxicity and survival experienced by patients with brain metastases in NCIC clinical trial group (CTG) trials
    Bradbury, Penelope A.
    Twumasi-Ankrah, Philip
    Ding Keyue
    Shepherd, Frances A.
    Goss, Glenwood
    Leighl, Natasha B.
    Laurie, Scott
    Seymour, Lesley
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S288 - S289
12345